Overview

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS
Phase:
Phase 2
Details
Lead Sponsor:
Sangamo Biosciences
Sangamo Therapeutics